SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Dec 3, 2019 South San Francisco / CA / USA - Genentech headquarters in San Francisco Bay Area; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009
Manufacturing
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Genentech, a member of the Roche Group, plans to open the facility in 2029 to ramp up capacity to make obesity candidates, including the dual GLP-1/GIP receptor agonist CT-388.
January 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Reaching an agreement. Businessmen shake hands and make a deal. vector
Collaboration
GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+
Ahead of GSK are Bristol Myers Squibb and Merck, which have already won FDA approvals for subcutaneous formulations of their respective PD-1 blockers Opdivo and Keytruda.
January 21, 2026
 · 
1 min read
 · 
Tristan Manalac
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
The obesity market and Most Favored Nation drug pricing were among the topics de jour at the J.P. Morgan Healthcare Conference last week, while smaller biotechs sought to assure investors that their regulatory ducks are in a row; Novo Nordisk’s oral obesity pill got off to a hot start while the FDA delayed a decision on Eli Lilly’s investigational offering; and SpyGlass Pharma and AgomAb Therapeutics join the 2026 IPO club.
January 21, 2026
 · 
1 min read
 · 
Heather McKenzie
Illustration showing abstract wavy background
Career Advice
Going With the Flow: Finding Success in Academic and Biotech Research Cultures
At some point in your research career, you may find yourself transitioning from academia to industry or vice versa. To best set yourself up for success, adapt your approach to the specific scientific culture where you work.
January 21, 2026
 · 
6 min read
 · 
Manali Shah
AI Medicine and Artificial intelligence in healthcare or Robot pharmacist and robotics in pharmacies as the future of prescription medication and health using machines and computer software for pharmaceutical technology.
Artificial intelligence
AI-Enabled Clinical Improvements Confirm Biotech Hype as Success Rates Rise
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
January 21, 2026
 · 
3 min read
 · 
Annalee Armstrong
Vector artwork depicts underdog wins.
Obesity
JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
January 20, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Brussels, Belgium. 21st December 2020. Exterior view of Pfizer Pharmaceutical company's offices.
Vaccines
Pfizer Makes $530M Vaccine Play With Novavax Deal After Rumors of BioNTech Pullback
In November, Pfizer was reportedly looking to divest its stake in BioNTech, though the German biotech at the time denied these rumors.
January 20, 2026
 · 
1 min read
 · 
Tristan Manalac
Facade of AstraZeneca's office in Shanghai, China
CAR-T
AstraZeneca Pays $630M for Complete Global Rights Over AbelZeta’s CAR T
The arrangement will boost AstraZeneca’s cell therapy portfolio as the pharma targets $80 billion in revenue by 2030.
January 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Poznan, Poland - 5 October 2024: GSK -Glaxosmithkline headquarters office building in Poznan.
Mergers & acquisitions
GSK Picks Up RAPT for $2.2B as Miels Makes First Move as CEO
The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, potentially setting up a competition for GSK with Roche’s Xolair.
January 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS